CXCR4 inhibitors can impair tumor growth and metastatic dissemination in HER2 enriched breast cancer cells but do not reduce tumor growth, and can increase metastatic spread of triple negative breast cancer. This evidence concerns the gene ERBB2 and neoplasm.